• HI-Bio

  • Teresita Arenzana Delfino

Teresita Arenzana Delfino

Associate Director | Translational Sciences at HI-Bio

Teresita Arenzana Delfino has a diverse work experience in the scientific research field. Teresita currently holds the position of Associate Director | Translational Sciences at HIBio since June 2022. Prior to this, they worked as a Principal Scientist at Tallac Therapeutics from May 2021 to May 2022. Before that, they held positions at Genentech, where they started as a Senior Scientific Researcher in July 2015 and progressed to become a Principal Scientific Researcher until April 2021. Teresita also has experience as a Postdoctoral Researcher at UCLA, where they worked from January 2009 to June 2015. Teresita began their career as a Graduate Student Researcher at Columbia University Vagelos College of Physicians and Surgeons from 2003 to 2008. Additionally, they worked as a QC Analyst at Genentech from July 2001 to August 2002.

Teresita Arenzana Delfino obtained a Bachelor of Science (BS) degree in Microbiology from the University of California, Davis, from 1997 to 2001. Afterward, they pursued further education and completed a Doctor of Philosophy (PhD) degree in Microbiology and Immunology from Columbia University Vagelos College of Physicians and Surgeons between 2002 and 2008.

Location

San Francisco, United States

Links


Org chart


Teams


Offices


HI-Bio

HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.


Employees

11-50

Links